z-logo
open-access-imgOpen Access
In-silico design of novel myocilin inhibitors for glaucoma therapy
Author(s) -
Min Tang,
Yang Fu,
Ying Fan,
Mingshui Fu,
Zhi Zheng,
Xun Xu
Publication year - 2017
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v16i10.29
Subject(s) - myocilin , in silico , virtual screening , autodock , docking (animal) , chemistry , computational biology , glaucoma , pharmacology , drug discovery , medicine , biochemistry , biology , open angle glaucoma , ophthalmology , nursing , gene
Purpose: To explore newer computational approaches in the design of novel myocilin inhibitors for the treatment of glaucoma.Methods: An in-silico virtual screening technique based on simulation of molecular docking was utilised to design a novel myocilin inhibitors for the treatment of  glaucoma. The designed novel molecules were theoretically evaluated to predict their pharmacokinetic properties and toxic effects. Lead molecules were screened out in virtual screening technique on the basis of low binding energies obtained in AutoDock based molecular docking simulation.Results: Out of ten top lead compounds screened, ZINC01729523 and ZINC04692015 were promising, having shown potent inhibition of myocilin, good pharmacokinetic properties and absence of any toxic effects.Conclusion: In-silico virtual screening of molecular libraries containing a large number of ligands is very useful for short-listing of potential lead molecules for further structure-based discovery of antiglaucoma-drugs.Keywords: Glaucoma, Myocilin, Docking, Virtual-screening, Autodock, Ligand, Drug design

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here